APO Research
Talk to an analyst

APO RESEARCH · REPORT

Type I Hyperlipoproteinemia Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Type I Hyperlipoproteinemia Drug Industry Growth and Trends Forecast to 2032

26 December 202594 pages

Choose your research edition.

Industry ResearchType I Hyperlipoproteinemia Drug Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Type I Hyperlipoproteinemia Drug Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Type I Hyperlipoproteinemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Type I Hyperlipoproteinemia Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Type I Hyperlipoproteinemia Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Type I Hyperlipoproteinemia Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Type I Hyperlipoproteinemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Type I Hyperlipoproteinemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Type I Hyperlipoproteinemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Type I Hyperlipoproteinemia Drug include Aegerion Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., uniQure N.V. and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Type I Hyperlipoproteinemia Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Type I Hyperlipoproteinemia Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Type I Hyperlipoproteinemia Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Type I Hyperlipoproteinemia Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Type I Hyperlipoproteinemia Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Type I Hyperlipoproteinemia Drug Market by Company

Aegerion Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

uniQure N.V.

Novartis AG

Type I Hyperlipoproteinemia Drug Segment by Type

Pradigastat Sodium

Lomitapide Mesylate

Alipogene Tiparvovec

ISIS-APOCIIIRx

CAT-2003

Others

Type I Hyperlipoproteinemia Drug Segment by Application

Hospital

Clinic

Others

Type I Hyperlipoproteinemia Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Type I Hyperlipoproteinemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Type I Hyperlipoproteinemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Type I Hyperlipoproteinemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Type I Hyperlipoproteinemia Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Type I Hyperlipoproteinemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Pradigastat Sodium Table 2. Major Company of Lomitapide Mesylate Table 3. Major Company of Alipogene Tiparvovec Table 4. Major Company of ISIS-APOCIIIRx Table 5. Major Company of CAT-2003 Table 6. Major Company of Others Table 7. Global Type I Hyperlipoproteinemia Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (W Units) Table 9. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Type I Hyperlipoproteinemia Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Type I Hyperlipoproteinemia Drug Sales by Type (2027-2032) & (W Units) Table 14. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Type I Hyperlipoproteinemia Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Type I Hyperlipoproteinemia Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (W Units) Table 19. North America Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (W Units) Table 21. Europe Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (W Units) Table 23. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (W Units) Table 25. Latin America Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (W Units) Table 27. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Type I Hyperlipoproteinemia Drug Industry Trends Table 29. Type I Hyperlipoproteinemia Drug Industry Drivers Table 30. Type I Hyperlipoproteinemia Drug Industry Opportunities and Challenges Table 31. Type I Hyperlipoproteinemia Drug Industry Restraints Table 32. Global Type I Hyperlipoproteinemia Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Company (2021-2026) Table 34. Global Type I Hyperlipoproteinemia Drug Sales by Company (2021-2026) & (W Units) Table 35. Global Type I Hyperlipoproteinemia Drug Sales Share by Company (2021-2026) Table 36. Global Type I Hyperlipoproteinemia Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Type I Hyperlipoproteinemia Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Type I Hyperlipoproteinemia Drug Major Company Production Sites and Headquarters Table 39. Global Type I Hyperlipoproteinemia Drug Company, Product Type & Application Table 40. Global Type I Hyperlipoproteinemia Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Type I Hyperlipoproteinemia Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Type I Hyperlipoproteinemia Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Type I Hyperlipoproteinemia Drug Sales by Region (2021-2026) & (W Units) Table 45. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Type I Hyperlipoproteinemia Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Type I Hyperlipoproteinemia Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Type I Hyperlipoproteinemia Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Type I Hyperlipoproteinemia Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Type I Hyperlipoproteinemia Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Type I Hyperlipoproteinemia Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Type I Hyperlipoproteinemia Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Type I Hyperlipoproteinemia Drug Sales by Application (2027-2032) & (W Units) Table 61. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Type I Hyperlipoproteinemia Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Type I Hyperlipoproteinemia Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (W Units) Table 66. North America Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (W Units) Table 68. Europe Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (W Units) Table 70. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (W Units) Table 72. Latin America Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (W Units) Table 74. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Application (2021-2026) & (US$ Million) Table 75. Aegerion Pharmaceuticals, Inc. Company Information Table 76. Aegerion Pharmaceuticals, Inc. Business Overview Table 77. Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio Table 79. Aegerion Pharmaceuticals, Inc. Recent Development Table 80. Catabasis Pharmaceuticals, Inc. Company Information Table 81. Catabasis Pharmaceuticals, Inc. Business Overview Table 82. Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio Table 84. Catabasis Pharmaceuticals, Inc. Recent Development Table 85. Isis Pharmaceuticals, Inc. Company Information Table 86. Isis Pharmaceuticals, Inc. Business Overview Table 87. Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio Table 89. Isis Pharmaceuticals, Inc. Recent Development Table 90. uniQure N.V. Company Information Table 91. uniQure N.V. Business Overview Table 92. uniQure N.V. Type I Hyperlipoproteinemia Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. uniQure N.V. Type I Hyperlipoproteinemia Drug Product Portfolio Table 94. uniQure N.V. Recent Development Table 95. Novartis AG Company Information Table 96. Novartis AG Business Overview Table 97. Novartis AG Type I Hyperlipoproteinemia Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Novartis AG Type I Hyperlipoproteinemia Drug Product Portfolio Table 99. Novartis AG Recent Development Table 100. North America Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 101. North America Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 102. North America Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2026) Table 103. North America Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032) & (W Units) Table 104. North America Type I Hyperlipoproteinemia Drug Sales Market Share Forecast by Country (2027-2032) Table 105. North America Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 106. North America Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 107. North America Type I Hyperlipoproteinemia Drug Market Share by Country (2021-2026) Table 108. North America Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 109. North America Type I Hyperlipoproteinemia Drug Market Share Forecast by Country (2027-2032) Table 110. Europe Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 111. Europe Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 112. Europe Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2026) Table 113. Europe Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032) & (W Units) Table 114. Europe Type I Hyperlipoproteinemia Drug Sales Market Share Forecast by Country (2027-2032) Table 115. Europe Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 116. Europe Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 117. Europe Type I Hyperlipoproteinemia Drug Market Share by Country (2021-2026) Table 118. Europe Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 119. Europe Type I Hyperlipoproteinemia Drug Market Share Forecast by Country (2027-2032) Table 120. Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 121. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 122. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2026) Table 123. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032) & (W Units) Table 124. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Market Share Forecast by Country (2027-2032) Table 125. Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 126. Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 127. Asia-Pacific Type I Hyperlipoproteinemia Drug Market Share by Country (2021-2026) Table 128. Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 129. Asia-Pacific Type I Hyperlipoproteinemia Drug Market Share Forecast by Country (2027-2032) Table 130. Latin America Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 131. Latin America Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 132. Latin America Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2026) Table 133. Latin America Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032) & (W Units) Table 134. Latin America Type I Hyperlipoproteinemia Drug Sales Market Share Forecast by Country (2027-2032) Table 135. Latin America Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 136. Latin America Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 137. Latin America Type I Hyperlipoproteinemia Drug Market Share by Country (2021-2026) Table 138. Latin America Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 139. Latin America Type I Hyperlipoproteinemia Drug Market Share Forecast by Country (2027-2032) Table 140. Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 141. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026) & (W Units) Table 142. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Market Share by Country (2021-2026) Table 143. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032) & (W Units) Table 144. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Market Share Forecast by Country (2027-2032) Table 145. Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 146. Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026) & (US$ Million) Table 147. Middle East and Africa Type I Hyperlipoproteinemia Drug Market Share by Country (2021-2026) Table 148. Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 149. Middle East and Africa Type I Hyperlipoproteinemia Drug Market Share Forecast by Country (2027-2032) Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Type I Hyperlipoproteinemia Drug Distributors List Table 153. Type I Hyperlipoproteinemia Drug Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Type I Hyperlipoproteinemia Drug Image Figure 2. Global Type I Hyperlipoproteinemia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Type I Hyperlipoproteinemia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Type I Hyperlipoproteinemia Drug Sales (2021-2032) & (W Units) Figure 5. Pradigastat Sodium Image Figure 6. Global Pradigastat Sodium Sales YoY Growth (2021-2032) & (W Units) Figure 7. Lomitapide Mesylate Image Figure 8. Global Lomitapide Mesylate Sales YoY Growth (2021-2032) & (W Units) Figure 9. Alipogene Tiparvovec Image Figure 10. Global Alipogene Tiparvovec Sales YoY Growth (2021-2032) & (W Units) Figure 11. ISIS-APOCIIIRx Image Figure 12. Global ISIS-APOCIIIRx Sales YoY Growth (2021-2032) & (W Units) Figure 13. CAT-2003 Image Figure 14. Global CAT-2003 Sales YoY Growth (2021-2032) & (W Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 17. Global Type I Hyperlipoproteinemia Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Type I Hyperlipoproteinemia Drug Market Share by Type 2025 VS 2032 Figure 19. North America Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Type I Hyperlipoproteinemia Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 37. Global Type I Hyperlipoproteinemia Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Type I Hyperlipoproteinemia Drug Market Share by Application 2025 VS 2032 Figure 39. North America Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Type I Hyperlipoproteinemia Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. North America Type I Hyperlipoproteinemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Type I Hyperlipoproteinemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Type I Hyperlipoproteinemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Type I Hyperlipoproteinemia Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Europe Type I Hyperlipoproteinemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Type I Hyperlipoproteinemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Type I Hyperlipoproteinemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Type I Hyperlipoproteinemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Type I Hyperlipoproteinemia Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Latin America Type I Hyperlipoproteinemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Type I Hyperlipoproteinemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Type I Hyperlipoproteinemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 66. Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Type I Hyperlipoproteinemia Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Type I Hyperlipoproteinemia Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Type I Hyperlipoproteinemia Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Pradigastat Sodium
  • Lomitapide Mesylate
  • Alipogene Tiparvovec
  • ISIS-APOCIIIRx
  • CAT-2003
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Aegerion Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • uniQure N.V.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Type I Hyperlipoproteinemia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Type I Hyperlipoproteinemia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Type I Hyperlipoproteinemia Drug Market by Type
  6. 1.3.1 Pradigastat Sodium
  7. 1.3.2 Lomitapide Mesylate
  8. 1.3.3 Alipogene Tiparvovec
  9. 1.3.4 ISIS-APOCIIIRx
  10. 1.3.5 CAT-2003
  11. 1.3.6 Others
  12. 1.4 Global Type I Hyperlipoproteinemia Drug Market Size by Type
  13. 1.4.1 Global Type I Hyperlipoproteinemia Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Type I Hyperlipoproteinemia Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Type I Hyperlipoproteinemia Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Type I Hyperlipoproteinemia Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Type I Hyperlipoproteinemia Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Type I Hyperlipoproteinemia Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Type I Hyperlipoproteinemia Drug Industry Trends
  2. 2.2 Type I Hyperlipoproteinemia Drug Industry Drivers
  3. 2.3 Type I Hyperlipoproteinemia Drug Industry Opportunities and Challenges
  4. 2.4 Type I Hyperlipoproteinemia Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Type I Hyperlipoproteinemia Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Type I Hyperlipoproteinemia Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Type I Hyperlipoproteinemia Drug Price (2021-2026)
  4. 3.4 Global Type I Hyperlipoproteinemia Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Type I Hyperlipoproteinemia Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Type I Hyperlipoproteinemia Drug Company, Product Type & Application
  7. 3.7 Global Type I Hyperlipoproteinemia Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Type I Hyperlipoproteinemia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Type I Hyperlipoproteinemia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Type I Hyperlipoproteinemia Drug Tier 1, Tier 2, and Tier 3
4 Type I Hyperlipoproteinemia Drug Regional Status and Outlook
  1. 4.1 Global Type I Hyperlipoproteinemia Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Type I Hyperlipoproteinemia Drug Historic Market Size by Region
  3. 4.2.1 Global Type I Hyperlipoproteinemia Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Type I Hyperlipoproteinemia Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Type I Hyperlipoproteinemia Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Type I Hyperlipoproteinemia Drug Forecasted Market Size by Region
  7. 4.3.1 Global Type I Hyperlipoproteinemia Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Type I Hyperlipoproteinemia Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Type I Hyperlipoproteinemia Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Type I Hyperlipoproteinemia Drug by Application
  1. 5.1 Type I Hyperlipoproteinemia Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Type I Hyperlipoproteinemia Drug Market Size by Application
  6. 5.2.1 Global Type I Hyperlipoproteinemia Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Type I Hyperlipoproteinemia Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Type I Hyperlipoproteinemia Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Type I Hyperlipoproteinemia Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Type I Hyperlipoproteinemia Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Type I Hyperlipoproteinemia Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Aegerion Pharmaceuticals, Inc.
  2. 6.1.1 Aegerion Pharmaceuticals, Inc. Company Information
  3. 6.1.2 Aegerion Pharmaceuticals, Inc. Business Overview
  4. 6.1.3 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio
  6. 6.1.5 Aegerion Pharmaceuticals, Inc. Recent Developments
  7. 6.2 Catabasis Pharmaceuticals, Inc.
  8. 6.2.1 Catabasis Pharmaceuticals, Inc. Company Information
  9. 6.2.2 Catabasis Pharmaceuticals, Inc. Business Overview
  10. 6.2.3 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio
  12. 6.2.5 Catabasis Pharmaceuticals, Inc. Recent Developments
  13. 6.3 Isis Pharmaceuticals, Inc.
  14. 6.3.1 Isis Pharmaceuticals, Inc. Company Information
  15. 6.3.2 Isis Pharmaceuticals, Inc. Business Overview
  16. 6.3.3 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Portfolio
  18. 6.3.5 Isis Pharmaceuticals, Inc. Recent Developments
  19. 6.4 uniQure N.V.
  20. 6.4.1 uniQure N.V. Company Information
  21. 6.4.2 uniQure N.V. Business Overview
  22. 6.4.3 uniQure N.V. Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 uniQure N.V. Type I Hyperlipoproteinemia Drug Product Portfolio
  24. 6.4.5 uniQure N.V. Recent Developments
  25. 6.5 Novartis AG
  26. 6.5.1 Novartis AG Company Information
  27. 6.5.2 Novartis AG Business Overview
  28. 6.5.3 Novartis AG Type I Hyperlipoproteinemia Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novartis AG Type I Hyperlipoproteinemia Drug Product Portfolio
  30. 6.5.5 Novartis AG Recent Developments
7 North America by Country
  1. 7.1 North America Type I Hyperlipoproteinemia Drug Sales by Country
  2. 7.1.1 North America Type I Hyperlipoproteinemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Type I Hyperlipoproteinemia Drug Market Size by Country
  6. 7.2.1 North America Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Type I Hyperlipoproteinemia Drug Sales by Country
  2. 8.1.1 Europe Type I Hyperlipoproteinemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Type I Hyperlipoproteinemia Drug Market Size by Country
  6. 8.2.1 Europe Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Type I Hyperlipoproteinemia Drug Sales by Country
  2. 9.1.1 Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Type I Hyperlipoproteinemia Drug Sales by Country
  2. 10.1.1 South America Type I Hyperlipoproteinemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Type I Hyperlipoproteinemia Drug Market Size by Country
  6. 10.2.1 South America Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Country
  2. 11.1.1 Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Type I Hyperlipoproteinemia Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Type I Hyperlipoproteinemia Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Type I Hyperlipoproteinemia Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Type I Hyperlipoproteinemia Drug Value Chain Analysis
  2. 12.1.1 Type I Hyperlipoproteinemia Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Type I Hyperlipoproteinemia Drug Production Mode & Process
  7. 12.2 Type I Hyperlipoproteinemia Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Type I Hyperlipoproteinemia Drug Distributors
  10. 12.2.3 Type I Hyperlipoproteinemia Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst